top of page

Innovative • Collaborative • Impactful

At microscopIA, we empower global health by harnessing interdisciplinary innovation, clinical expertise, and policy-driven solutions to transform healthcare delivery and quality

A boy holding a donation box
Favelas

How It All Started

Since February 2023, microscopIA has not only provided research services to third parties but also launched its own independent global health projects. Driven by a dynamic collaboration among physicians, engineers, researchers, and students across various countries, our initiatives focus on enhancing healthcare access and quality—especially in underserved, rural, and remote areas.

Baby with Toys

Initiative for Retinopathy of Prematurity

Our initiative unites clinicians, engineers, and policymakers to generate robust evidence and shape strategies that prevent blindness. Through innovative collaboration, we drive early detection and cost-effective interventions to protect vision worldwide.

we also develop prototypes for diagnostics

automated microscope for malaria and tropical diseases

  • Urban-Rural Disparities in Obstetric Intensive Care Utilization and Outcomes
    Status: Under Peer-Review This study investigates disparities in obstetric intensive care resource utilization and patient outcomes between urban and rural settings. It also assesses the cost-effectiveness of a hybrid antenatal care model that combines in-person consultations with telemedicine services. The goal is to generate evidence that informs policy decisions and optimizes resource allocation, ultimately ensuring equitable access to high-quality obstetric care across diverse populations.
  • Prophylactic Ophthalmic Ketorolac for Early-Stage Retinopathy of Prematurity
    Status: Under Peer-Review Our project evaluates the clinical and economic impact of using prophylactic ophthalmic ketorolac in early-stage retinopathy of prematurity. By generating robust, real-world evidence, we support the integration of ketorolac—and similar NSAIDs—into clinical guidelines as a cost-effective intervention to reduce disease progression and prevent blindness, particularly for infants with limited screening follow-up.
  • Prophylactic Ophthalmic Nepafenac for Early-Stage Retinopathy of Prematurity
    Status: Data collection Our project evaluates the clinical and economic impact of using prophylactic ophthalmic ketorolac in early-stage retinopathy of prematurity. By generating robust, real-world evidence, we support the integration of nepafenac—and similar NSAIDs—into clinical guidelines as a cost-effective intervention to reduce disease progression and prevent blindness, particularly for infants with limited screening follow-up.
  • Prophylactic Ophthalmic Ketorolac and Nepafenac in Early-Stage Retinopathy of Prematurity and Their Impact on Outcomes in Advanced Stage Disease
    Status: Under Peer-Review This study investigates the use of prophylactic ophthalmic ketorolac and nepafenac in early-stage retinopathy of prematurity (ROP) and examines their influence on clinical outcomes in infants who progress to advanced stage disease. By analyzing progression rates, quality-adjusted life years, and ROP-management costs, the research aims to determine whether early prophylaxis can stabilize retinal development and mitigate the severity of advanced ROP. The findings will provide critical insights to refine treatment protocols and enhance care strategies for high-risk preterm infants.
  • Ranibizumab and Bevacizumab for Advanced Stage Retinopathy of Prematurity
    Status: Under Peer-Review This study compares the cost effectiveness of single intravitreal injections of ranibizumab and bevacizumab used as the first line of monotherapy for advanced stage retinopathy of prematurity. By analyzing clinical outcomes, quality-adjusted life years, and overall treatment costs, the project aims to determine which anti-vascular endothelial growth factor agent provides the greatest economic value without compromising patient care. The findings will inform clinical guidelines and help optimize resource allocation, particularly in settings with limited healthcare budgets.
  • Geospatial Distribution of Intensive Care Units in Colombia
    Status: Data Analysis This study examines the geographic distribution of intensive care units across Colombia, using geospatial mapping techniques to identify regional disparities and resource allocation patterns. By visualizing ICU locations, capacities, and accessibility, the analysis reveals critical gaps in critical care infrastructure—especially in rural and underserved areas. The insights gained aim to inform policymakers and healthcare planners on optimizing resource distribution to improve patient access and overall healthcare outcomes.
  • Geospatial Distribution of Retinopathy of Prematurity Resources in Colombia
    Status: Data Collection This study maps the spatial distribution of retinopathy of prematurity (ROP) resources in Colombia, including healthcare infrastructure and the availability of specialized clinicians. By employing geospatial analysis, the research identifies regional disparities and key gaps in access to ROP care, providing critical insights to inform targeted policy interventions and optimize resource allocation for improving neonatal eye health outcomes.
  • Geospatial Distribution of Solid Organ, Bone Marrow, and Cornea Transplantation Resources in Colombia
    Status: Data Collection This study employs geospatial analysis to map the availability of solid organ, bone marrow, and cornea transplant services across Colombia. By identifying regional disparities in transplant infrastructure—including hospitals, specialized centers, and expert clinicians—the research aims to pinpoint gaps in access to life-saving procedures. The findings will inform policymakers and healthcare planners to optimize resource allocation and improve equity in transplant care nationwide.
  • Transitioning from Incremental Cost Effectiveness Ratio to Net Monetary Benefit for Enhanced Health Economic Evaluations
    Status: Manuscript Preparation This project critically examines the limitations of the incremental cost-effectiveness ratio (ICER) in settings where clinical benefits are marginal and demonstrates that the net monetary benefit (NMB) offers a more stable and interpretable metric. Drawing on microscopIA’s real-world research, the study employs probabilistic sensitivity analysis and bootstrap resampling to compare ICER and NMB outcomes. The findings provide clear methodological recommendations to improve the precision of economic evaluations and support more informed healthcare policy and resource allocation decisions.
  • Photon-Counting Detectors for Mammography Screening
    Status: Manuscript Preparation This project evaluates the potential of introducing photon-counting detectors based on CERN technology into mammography screening, focusing on a 30-year implementation horizon. By integrating advanced technical parameters—such as superior contrast-to-noise ratio and reduced radiation dose—with comprehensive clinical and economic analyses, the study translates sensor performance into quality-adjusted life years and net monetary benefits. Using probabilistic sensitivity analysis and dynamic return on investment, the research aims to bridge the gap between cutting-edge innovation and real-world healthcare improvements, informing policy and guiding the adoption of transformative breast cancer detection technologies.
  • Hybrid Non-Invasive Monitoring for Kidney Transplant Rejection Integrating Shear Wave Elastography, Laboratory Testing, and Mobile Clinics
    Status: Manuscript Preparation This study evaluates a hybrid non-invasive approach for monitoring kidney transplant rejection that integrates shear wave elastography with combined blood and urine laboratory testing. By comparing facility-based and mobile clinic models, the research addresses challenges in healthcare access for rural and remote patients. Using probabilistic Monte Carlo modeling, the study assesses diagnostic accuracy, quality-adjusted life years, and overall cost-effectiveness relative to traditional biopsy methods. The findings aim to inform healthcare policy and optimize resource allocation, ensuring equitable access to advanced transplant rejection monitoring.
  • Determinants of Non-Adherence in the Screening and Treatment of Retinopathy of Prematurity
    Status: Ethics Committee and Study Design This prospective, multicenter observational study aims to identify and analyze the socioeconomic, cultural, and structural factors that influence non-adherence to retinopathy of prematurity (ROP) management. By systematically following patients across multiple clinical centers, the study will evaluate the familial, logistical, and coordination barriers between caregivers and the healthcare system. The findings will inform the development of an integrated intervention strategy to optimize care, improve therapeutic and visual outcomes, and provide evidence-based recommendations for health policy. Additionally, the clinical data generated will serve as a foundation for secondary studies and future publications, enhancing collaboration and knowledge in the field of ROP management.
  • Mental Health of Venezuelan Immigrant School-Age Children and Adolescents Compared to Colombian Peers
    Status: Ethics Committee and Study Design This study examines the mental health outcomes of Venezuelan immigrant children and adolescents in comparison with their Colombian peers. By utilizing standardized assessments, surveys, and interviews, the research explores differences in the prevalence of mental health challenges, resilience factors, and the impact of cultural integration, socioeconomic conditions, and family support. The findings aim to inform tailored mental health interventions and policy strategies to support the well-being and successful integration of vulnerable immigrant populations in Colombia.
microscopIA.png
bottom of page